Protein A compositions and methods of use

Details Protein A compositions and methods of use Protein A compositions and methods of use

2006-11-14

2010-10-05

Belyavskyi, Michail A (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S185100, C424S577000

Reexamination Certificate

active

07807170

ABSTRACT:
Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 μg.

REFERENCES:
patent: 4315028 (1982-02-01), Scheinberg
patent: 4355029 (1982-10-01), Ridolfo
patent: 4402965 (1983-09-01), Wyburn-Mason
patent: 4479934 (1984-10-01), Sedlacek et al.
patent: 4617266 (1986-10-01), Fahnestock
patent: 4628052 (1986-12-01), Peat
patent: 4681870 (1987-07-01), Balint, Jr. et al.
patent: 4699783 (1987-10-01), Terman et al.
patent: 4719107 (1988-01-01), Carosella et al.
patent: 4816441 (1989-03-01), Zeuthen et al.
patent: 4863869 (1989-09-01), Balint
patent: 4925920 (1990-05-01), Mannick et al.
patent: 5077284 (1991-12-01), Loria et al.
patent: 5084398 (1992-01-01), Huston et al.
patent: 5084559 (1992-01-01), Profy
patent: 5091091 (1992-02-01), Terman
patent: 5122112 (1992-06-01), Jones
patent: 5189014 (1993-02-01), Cowan, Jr.
patent: 5230887 (1993-07-01), Hoffmann et al.
patent: 5277701 (1994-01-01), Christie et al.
patent: 5324707 (1994-06-01), Yokoyama et al.
patent: 5362490 (1994-11-01), Kurimoto et al.
patent: 5422427 (1995-06-01), Russell et al.
patent: 5470578 (1995-11-01), Aoki et al.
patent: 5633145 (1997-05-01), Feldmann et al.
patent: 5662909 (1997-09-01), Becker et al.
patent: 5741488 (1998-04-01), Feldman et al.
patent: 5782792 (1998-07-01), Jones et al.
patent: 5877147 (1999-03-01), Pinegin
patent: 5958966 (1999-09-01), Mann et al.
patent: 5965400 (1999-10-01), Briles et al.
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 5997496 (1999-12-01), Sekiguchi et al.
patent: 6013763 (2000-01-01), Braisted et al.
patent: 6039946 (2000-03-01), Strahilevitz
patent: 6042837 (2000-03-01), Kalland et al.
patent: 6117421 (2000-09-01), Morton et al.
patent: 6221351 (2001-04-01), Terman
patent: 6242427 (2001-06-01), Schreiber et al.
patent: 6245340 (2001-06-01), Youssefyeh
patent: 6251385 (2001-06-01), Terman
patent: 6312944 (2001-11-01), Russell et al.
patent: 6447777 (2002-09-01), Terman et al.
patent: 6555661 (2003-04-01), Torres et al.
patent: 7163686 (2007-01-01), Silverman
patent: 7211258 (2007-05-01), Mann
patent: 91/19509 (1991-12-01), None
patent: 97/36614 (1997-10-01), None
patent: 00/69457 (2000-11-01), None
Benny et al.; Clinical Evaluation of aStaphylococcalProtein A Immunoadsorption System in the Treatment of Myasthenia Gravis Patients;Transfusion, 1999; 39: 682-687.
Caldwell, J., et al., a Pilot Study Using a Staph Protein A Column (Prosorba) to Treat Refractory Rheumatoid Arthritis, J.. Rheumatology, 26:8:1657-1662 (1999).
Catalona, W.J., et al., λLambda Inteferon Induced byS. aureusProtein A Augments Natural Killing and ADCC, Nature, 291:77-79- (1981).
Cochlovius, B., et al., Therapeutic Antibodies, Modern Drug Discovery, Oct. 2003, 33-38.
Das et al., “Induction of Cell Proliferation and Apoptosis: Dependence on the Dose of the Inducer”,Biochemical and Biophysical Research Communications, 1999; 260(1): 105-110.
Das et al., “Protein A-Activated Rat Splenic Lymphocyte Proliferation Involves Tyrosine Kinase-Phospholipase C-Protein Kinase C Pathway”,Immunopharmacology and Immunotoxicology, 2000; 22(1): 75-90.
Ezepchuk, Yuri et al.,StaphylococcalToxins and Protein A Differentially Induce Cytotoxicity and Release of Tumor Necrosis Factor-{acute over (α)} From Human Keratinocytes, The Journal of Investigative Dermatology, 107(4):603-609 (1996).
Feldman, Anti-TNFα Therapy Is Useful in Rheumatoid Arthritis and Crohn's Disease: Analysis of the Mechanism of Action Predicts Utility in Other Diseases, Transplantation Proceedings, 30:4126-4127 (1998).
Felson, D., et al., The Prosorba Column for Treatment of Refractory Rheumatoid Arthritis, Arthritis & Pheumatism, 42:2153-2159 (1999).
Friedman et al., “Microbial Superantigens as Etiopathogenic Agents in Autoimmunity”,Controversies in Clinical Rheumatology, 1993; 19(1): 207-222.
Ghosh et al., “Protection by Protein-A of Apoptotic Cell Death Caused by Anti-AIDS Drug Zidovudine”,Biochemical and Biophysical Research Communications, 1999; 264(2): 601-604.
Ghosh, A.K., et al.,S. aureusSuperantigen Protein A Expands CD4+/CD8+/CD19+/CD34+ Cells in Mice: A Potential Immunorestorer, Biochemical and Biophysical Research Communications, 142-146 (1999).
Goodyear et al., “Evidence Of A Novel Immunomodulatory Mechanism Of Action Of Prosorba Therapy: Release OfStaphyloccoccalProtein A Induces VHRegion Targeted Apoptotic Death Of B Lymphocytes”,Merck's Rheumatology Young Investigators' Program, Nov. 14, 2000: S296, Abstract #1462.
Graille, Marc et al., Crystal structure of aStaphylococcus aureusprotein A domain complexed with the Fab fragment of a human IgM antibody: Structural basis for recognition of B-cell receptors and superantigen activity, PNAS, 97(10):5399-5404.
He et al., “Selective Induction of Rheumatoid Factors by Superantigens and Human Helper T Cells”,J. Clin. Invest., 1992; 89: 673-680.
Kozlowski et al., “In Vivo Inflammatory Response to a Prototypic B Cell Superantigen: Elicitation of an Arthus Reaction byStaphylococcalProtein A”,Journal of Immunology, 1998; 160: 5346-5252.
Kozlowski et al., “Staphylococcus aureusCowan I-Induced Human Immunoglobulin Responses: Preferential IgM Rheumatoid Factor Production and VH3 mRNA Expression by Protein A-Binding B Cells”,Journal of Clinical Immunology, 1995; 15(3): 145-151.
Levinson et al., “Prominent IgM Rheumatoid Factor Production by Human Cord Blood Lymphocytes Stimulated in Vitro WithStaphylococcus aureusCowan I”,Journal of Immunology, 1987; 139(7): 2237-2241.
Levinson et al., “Staphylococcus aureusCowan I: Potent Stimulus of Immunoglobulin M Rheumatoid Factor Production”, Journal of Clinical Investigation, 1986; 78(3): 612-617.
Levinson, et al., “IgM Rheumatoid Factor Produced in Response toS. AureusCowan I: Role of Protein A and Preferential Utilization of VH3 Heavy Chains”,The Journal of Immunology, 1993; 150(8), Part 2, Abstract #1355.
Matic et al., “Background and Indications for Protein A-Based Extracorporeal Immunoadsorption”,Therapeutic Apheresis, 2001; 5(5): 394-403.
Mestas, J., et al., Of Mice and Not Men: Differences Between Mouse and Human Immunology, The Journal of Immunology, 172:2731-2738 (2004).
Mourad et al., “Engagement of Major Histocompatibility Complex Class II Molecules by Superantigen Induces Inflammatory Cytokine Gene Expression in Human Rheumatoid Fibroblast-like Synoviocytes,”J. Exp. Med., 1992; 175: 613-616.
Nardella et al., “IgG Rheumatoid Factors andStaphylococcalProtein A Bind to A Common Molecular Site on IgG,”The Journal of Experimental Medicine, 1985; 162(6): 1811-1823.
Paliard, X., et al., Evidence for the Effects of a Superantigen in Rheumatoid Arthritis, Science, 325-329 (1991).
Paul, W.E., et al., Fundamental Immunology, 1998, Lippincott-Raven Publisher, pp. 788, 1105.
Rheumawire Dec. 7, 2001 (BR) New mechanism of action proposed for Prosorba column, http://ww.joihtandbone.org
ews/200112
ews20011207a.cfm.
Romagnani, S., et al., Surface Immunoglobulins are Involved in the Interaction of Protein A with Human B Cells and in the Triggering of b Cell Proliferation Induced by Protein A-ContainingStaphylococcus aureus, The Journal of Immunology, 1307-1313 (1981).
Samtleben, W., et al., Ex vivo and in vivo Protein A Perfusion: Background, Basic Investigations, and First Clinical Experiances, Blood Purification, 5:179-192 (1987).
Schneider, M., et al., Immunoadsorption in Systemic Connective Tissue Diseases and Primary Vasculitis, Therapeutic Apheresis, 1(2):117-120 (1997).
Silverman et al., “A B Cell Superantigen-induced Persisent “Hole” in the B-1 Repertoire”,J. Exp. Med., 2000;192(1): 87-98.
S

Affiliated with

Also associated with

Rating

Protein A compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protein A compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein A compositions and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4179724